When is Heartflow the better choice?

The coronary computed tomography analysis is the product, quantifying plaque and stenosis in a way that changes the downstream care pathway rather than the reading order. The clinical evidence base in cardiac imaging is deep and the outcome being changed is invasive testing avoided, which is measurable in both cost and patient risk. For a cardiology service the question is which patients need the catheterisation laboratory, and that is what this answers.

When is Viz.ai the better choice?

Its stroke product received the first ever authorization for computer aided triage and notification, and the platform's real work is mobilising the treating team. The evidence measures care delivery rather than detection accuracy, which is the harder result and the one that corresponds to patient benefit. For a time critical pathway the constraint is coordination rather than interpretation, and the communication layer is the product.

Heartflow vs Viz.ai

Last VerifiedAugust 4, 2026

Verdict

Both change what happens after a scan rather than only what a radiologist sees in it, in different cardiovascular pathways. Heartflow analyses coronary computed tomography to quantify plaque and stenosis, and the outcome it moves is whether a patient goes to the catheterisation laboratory at all, which is measurable in cost and in avoided procedural risk. Viz.ai detects and then mobilises, holding the first ever authorization for computer aided triage and notification, with evidence measuring care delivery rather than model accuracy. A cardiology service and a stroke service would each buy one and not the other. What both illustrate is the same lesson: the imaging AI that pays for itself is the one wired into a decision, not the one that produces a better description of the image.

Select Heartflow if

The coronary computed tomography analysis is the product, quantifying plaque and stenosis in a way that changes the downstream care pathway rather than the reading order.
The clinical evidence base in cardiac imaging is deep and the outcome being changed is invasive testing avoided, which is measurable in both cost and patient risk.
For a cardiology service the question is which patients need the catheterisation laboratory, and that is what this answers.

Select Viz.ai if

Its stroke product received the first ever authorization for computer aided triage and notification, and the platform's real work is mobilising the treating team.
The evidence measures care delivery rather than detection accuracy, which is the harder result and the one that corresponds to patient benefit.
For a time critical pathway the constraint is coordination rather than interpretation, and the communication layer is the product.

Attribute Matrix

Side by Side

Axis	H Heartflow	V Viz.ai
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.

Aidoc vs Heartflow→Lunit vs Viz.ai→Qure AI vs Viz.ai→Rad AI vs Viz.ai→

Disclosure

These sit in different cardiovascular workflows and are compared because both change what happens after the scan rather than only what is seen in it. Viz.ai publishes no independent security attestation and no business associate terms, and no hosting or residency terms were located. Neither publishes subgroup performance, which matters in cardiac imaging because plaque characterisation and stroke presentation both vary by sex and the evidence bases historically under represent women. Neither publishes pricing.